Original articles
Pengxing He, Shenghui Niu, Shuai Wang, Xiaojing Shi, Siqi Feng, Linna Du, Xuyang Zhang, Zhilu Ma, Bin Yu, Hongmin Liu. Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor[J]. Acta Pharmaceutica Sinica B, 2019, 9(6): 1193-1203

Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor
Pengxing Hea, Shenghui Niua, Shuai Wanga, Xiaojing Shia, Siqi Fenga, Linna Dua, Xuyang Zhanga, Zhilu Maa, Bin Yua,b, Hongmin Liua
a School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China;
b State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, China
Abstract:
EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors. In the present study, we reported the discovery of WS-157 from our in-house diverse compound library, which was validated to be a potent and selective EGFR-TKI. WS-157 showed excellent inhibitory activities against EGFR (IC50=0.81 nmol/L), EGFR[d746-750] (IC50=1.2 nmol/L) and EGFR[L858R] (IC50=1.1 nmol/L), but was less effective or even inactive against other nine kinases. WS-157 also displayed excellent antiproliferative activities against a panel of human cancer cell lines, and exhibited the ability to reduce colony formation and wound healing the same as gefitinib. We found that WS-157 upon oral administration showed better anti-tumor activity in A431 bearing xenograft mouse models compared to gefitinib. In addition, WS-157 showed better intestinal absorption than gefitinib and had favorable pharmacokinetic properties and microsomal metabolic stability in different species. These studies indicate that WS-157 has strong antitumor activity in vitro and in vivo, and could be used for the development of anti-lung cancer agent targeting EGFR.
Key words:    WS-157    Tyrosine kinase    EGFR inhibitor    Antitumor activity   
Received: 2019-04-07     Revised: 2019-06-19
DOI: 10.1016/j.apsb.2019.06.010
Funds: This work was supported by the National Natural Science Foundation of China (Nos. 81430085 and 81773562 for Hongmin Liu and No. 81703326 for Bin Yu), the Open Fund of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China (No. KF-GN-201902 for Bin Yu, China), Natural Science Foundation of He'nan Province of China (No. 162300410303 for Pengxin He, China), Scientific Program of Henan Province (No. 182102310123 for Bin Yu, China), China Postdoctoral Science Foundation (No. 2015M572123 for Pengxing He and Nos. 2018M630840 and 2019T120641 for Bin Yu), Key Research Program of Higher Education of Henan Province (No. 18B350009 for Bin Yu, China).
Corresponding author: Bin Yu, Hongmin Liu     Email:yubin@zzu.edu.cn;liuhm@zzu.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Pengxing He
Shenghui Niu
Shuai Wang
Xiaojing Shi
Siqi Feng
Linna Du
Xuyang Zhang
Zhilu Ma
Bin Yu
Hongmin Liu

References:
1. Sun QM, Miao ZH, Lin LP, Gui M, Zhu CH, Xie H, et al. BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities. Cancer Biol Ther 2014;8:1640-7.
2. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007;19: 124-34.
3. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
4. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
5. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem 2011;54:8030-50.
6. Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, et al. Tyrosine kinase inhibitors. 15.4-(Phenylamino) quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 1999;42:1803-15.
7. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 2003;46:49-63.
8. Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, Xu Y, et al. Structural optimization and structure-activity relationships of N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. J Med Chem 2012;55: 10685-99.
9. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, et al. Studies leading to the identification of ZD1839 (IRESSATM): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-4.
10. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48.
11. Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012;76:177-82.
12. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin Cancer Res 2008;14:2895-9.
13. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
14. Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 2008;9:1336-46.
15. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50.
16. Food and Drug Administration. Public Health Service, U.S. Department of Health and Human Services. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms. J Pain Palliat Care Pharmacother 2012;26:123-6.
17. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372:1700-9.
18. Li ZR, Suo FZ, Hu B, Guo YJ, Fu DJ, Yu B, et al. Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor. Bioorg Chem 2019;84:164-9.
19. Greig SL. Osimertinib: first global approval. Drugs 2016;76:263-73.
20. Zhang X, Peng T, Ji X, Li J, Tong L, Li Z, et al. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urealinked side chains as inhibitors of the epidermal growth factor receptor. Bioorg Med Chem 2013;21:7988-98.
21. Deng X, Okram B, Ding Q, Zhang J, Choi Y, Adrián FJ, et al. Expanding the diversity of allosteric Bcr-Abl inhibitors. J Med Chem 2010;53:6934-46.
22. He PX, Zhang J, Che YS, He QJ, Chen Y, Ding J. G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation. Acta Pharmacol Sin 2014;35:1546-55.
23. He PX, Che YS, He QJ, Chen Y, Ding J. G226, a novel epipolythiodioxopiperazine derivative, induces autophagy and caspasedependent apoptosis in human breast cancer cells in vitro. Acta Pharmacol Sin 2014;35:1055-64.
24. Zhang J, Wang Y, Shen Y, He P, Ding J, Chen Y. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1. Theranostics 2018;8:2884-95.
25. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
26. Walgren RA, Walle T. The influence of plasma binding on absorption/exsorption in the Caco-2 model of human intestinal absorption. J Pharm Pharmacol 1999;51:1037-40.
27. Li Z, Ding L, Li Z, Wang Z, Suo F, Shen D, et al. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A). Acta Pharm Sin B 2019;9:794-808.
28. Wang S, Zhao L, Shi XJ, Ding L, Yang L, Wang ZZ, et al. Development of highly potent, selective, and cellular active triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 protein-protein interaction. J Med Chem 2019;62: 2772-97.
29. Yuan S, Yu B, Liu HM. Brønsted acid-catalyzed direct C (sp2)-H heteroarylation enabling the synthesis of structurally diverse biaryl derivatives. Adv Synth Catal 2019;361:59-66.
30. Blay J, Valentine-Braun KA, Northup JK, Hollenberg MD. Epidermal-growth-factor-stimulated phosphorylation of calpactin II in membrane vesicles shed from cultured A-431 cells. Biochem J 1989;259:577-83.
31. Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, ÖzvegyLaczka C, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol 2012;84:260-7.
32. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66:4802-7.
33. Chang L, Xiao M, Yang L, Wang S, Wang SQ, Bender A, et al. Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR). Bioorg Med Chem 2018;26:5006-17.
34. Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B 2015;5:390-401.
35. Zhang Z, Guo X, To K, Chen Z, Fang X, Luo M, et al. Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo. Acta Pharm Sin B 2018;8:563-74.